Evolving Solutions To Optimize Clinical Trial Decentralization

By Tim Rich, Vice President, Digital and Decentralized Solutions, PPD, Part of Thermo Fisher Scientific, and John Musaus, Head of Medication Adherence and Biomarker Measurement, Thermo Fisher Scientific

The benefits offered by decentralized trials are driving wider adoption of this approach to clinical research. The introduction of novel solutions to facilitate adherence can support decentralized trials and mitigate potential concerns surrounding reduced patient-physician touchpoints.

Now that PPD is part of the Thermo Fisher family, it is uniquely positioned to provide new, fit-for-purpose solutions to help sponsors create a better patient experience and realize the benefits of decentralized trials while assuring that those studies yield high-quality data. This article highlights Thermo Fisher's solutions to drive high adherence in decentralized trials.